The expression of FBXL5 was also found to be significantly downregulated in CD34+ progenitor cells of patients with RARS, a subtype of MDS characterized by iron deposition in hematopoietic progenitor cells. Here, FBXL5 is linked to myelodysplastic syndrome with ring sideroblasts.